NCI-2025-01859

Phase 2 Study of Zelenectide Pevedotin in Participants with NECTIN4 Amplified Advanced Breast Cancer

This Phase 2 research study is studying a new experimental drug called Zelenectide Pevedotin in people who have advanced or metastatic breast cancer that shows high levels (amplification) of a protein called NECTIN4. NECTIN4 is found on the surface of some cancer cells and helps them grow and spread. Zelenectide Pevedotin is designed to specifically target and attack cells that have NECTIN4, delivering a cancer-killing substance directly to them while trying to spare normal cells.

The purpose of this research study is to see how effective the drug is at shrinking or controlling tumors, and to monitor its safety and side effects in participants. Since it’s a Phase 2 study, it focuses on whether the treatment shows enough benefit to move forward to larger studies.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

Advanced: Advanced breast cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06840483

Clinical Trial Site: Sinai

To see all available clinical trials click here.